New Nitro PDF Pro Release Enables Accessible, Inclusive and Compliant PDFs for All
18.5.2023 16:57:00 EEST | Business Wire | Press release
Nitro Software, a global leader in SaaS PDF, eSign and business document solutions, launched new document accessibility features as part of the latest release of Nitro PDF Pro, its flagship product. Driven by its mission to provide easy-to-use, inclusive and compliant technology for all people and organizations, Nitro teamed up with digital accessibility solution provider Level Access.
“Everyone deserves access to digital information, and that includes the more than 1.3 billion people globally who identify as having a disability,” says Jonathon Avila, Chief Accessibility Officer at Level Access. “It has been deeply rewarding to support Nitro in providing innovative solutions that contribute to a more accessible digital world.”
Why do organizations need tools to create accessible PDF documents?
Document accessibility features are used by people with a range of needs, including those who are blind or have low vision. For organizations, particularly in higher education and government, accessibility features have a far-reaching and long-term impact on goals including:
Inclusivity: All people, including people with disabilities, should be equipped with technology that enables their success. With document accessibility tools, people with disabilities can participate and contribute equitably in education, the professional world and their communities.
Recruiting: Meeting the needs of all employees is a key differentiator for organizations during the recruiting and hiring process. Companies that prioritize the accessibility of documents and other digital information are at an advantage when competing for diverse talent.
Compliance: Many organizations are legally required to procure technology that meets accessibility compliance standards.
How is Nitro making documents more accessible and inclusive?
The latest Nitro PDF Pro release provides an intuitive solution for a vast and growing market seeking reliable tools that ensure document accessibility, inclusivity and compliance.
“Whether permanent, temporary or situational, we are all likely to experience disabilities in our lives. Nitro is a diverse and inclusive company, and we are proud that our latest release of Nitro PDF Pro provides capabilities for equal access to PDFs in the workplace, classroom, at home and everywhere in between,” says Sam Thorpe, Nitro’s Chief Product Officer. “The partnership with Level Access has been exceptionally valuable to ensure the software we design is aligned to the accessibility needs of people and organizations around the world.”
New features and enhancements in the latest release of Nitro PDF Pro include:
-
Accessibility features making it fast and easy to create accessible, compliant PDFs, such as:
- Auto-tagging documents, tables and lists in a few simple steps
- Assigning accessibility tags, roles and reading order in tagged PDFs
- Managing artifacts
- Specifying human languages of tagged PDFs
- Embedding fonts
- Supplying alternate text
- Marking PDF/UA compliance
- Fresh new UI with a modern, easy-to-navigate experience
- Expanded list of language installers
To learn more about creating accessible and compliant PDFs, join Nitro and Level Access for an educational webinar on June 8, 2023.
Explore more of what’s new in the latest release of Nitro PDF Pro.
About Nitro Software
Nitro is a global SaaS leader in PDF document management and eSigning. Nitro’s Productivity Platform includes powerful PDF tools, digital workflow automation, highly secure eSigning and identity capabilities. Its analytics solution measures and quantifies ROI, usage and sustainability impact. With a best-in-class customer success team, Nitro supports more than 67% of the Fortune 500, 3 million licensed users and 13,000+ business customers across 157 countries. For more information: visit https://gonitro.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005546/en/
Contact information
Media Contacts
Nitro Software media@gonitro.com
Bospar for Nitro Software prfornitro@bospar.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom